Hong Kong Baptist University and Elsevier Report Charts Global Growth of Chinese Medicine Research, Calls for Standardised Frameworks for Broader Integration
HKBU and Elsevier launched a new report 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine', highlighting the growing global impact of Chinese Medicine research in diversified healthcare solutions.
ISTANBUL, TURKEY – Media OutReach Newswire – 17 June 2025 – The report 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine' released today by Hong Kong Baptist University (HKBU) and Elsevier, reveals the growing impact of Chinese Medicine research on global healthcare and modern health challenges. In this context, 'Chinese Medicine research' encompasses not only clinical practice, but also basic and translational science, AI-driven systems medicine, and the network pharmacology of herbal formulas. This first bibliometric analysis of Chinese Medicine research from 2014 to 2023 highlights the field's rapid growth, interdisciplinarity, and societal impact on Digital Health and Systems Medicine.
Key findings from the report include:
Rapid expansion : Chinese Medicine research grew at a 10.6% compound annual growth rate — more than double the global research average — nearly tripling output between 2014 and 2023.
: Chinese Medicine research grew at a 10.6% compound annual growth rate — more than double the global research average — nearly tripling output between 2014 and 2023. High scholarly impact : 14.2% of Chinese Medicine papers ranked among the world's top 10% most-cited (global norm: 10%), with a field-weighted citation impact (FWCI) of 1.12.
: 14.2% of Chinese Medicine papers ranked among the world's top 10% most-cited (global norm: 10%), with a field-weighted citation impact (FWCI) of 1.12. Interdisciplinary breadth : Medicine dominates (61.9% of output), followed by Biochemistry, Genetics & Molecular Biology (33.1%) and Pharmacology (28.1%). Citing publications span diverse major domains — from Engineering to Materials Science.
: Medicine dominates (61.9% of output), followed by Biochemistry, Genetics & Molecular Biology (33.1%) and Pharmacology (28.1%). Citing publications span diverse major domains — from Engineering to Materials Science. Global collaboration hubs : Hong Kong SAR and Macao SAR exceed 80% cross-regional collaboration, above the 18% world average, and achieving FWCI >1.6 in cross-regional collaborative publications.
: Hong Kong SAR and Macao SAR exceed 80% cross-regional collaboration, above the 18% world average, and achieving FWCI >1.6 in cross-regional collaborative publications. Emerging research foci : Top-published trending topics include 'Herbaceous Agent | Chinese Medicine | Network Pharmacology' and COVID-19 applications, reflecting integration of omics, AI and systems methods.
: Top-published trending topics include 'Herbaceous Agent | Chinese Medicine | Network Pharmacology' and COVID-19 applications, reflecting integration of omics, AI and systems methods. Societal resonance: 11.1% of research outputs were mentioned on social media and 2.9% cited in policy documents, reflecting growing public and policymaker interest.
Bridging a global integration gap
ADVERTISEMENT
Chinese Medicine's mainstream integration lacks a global, transparent, evidence-based framework. To elevate its scientific profile, key strategies include developing internationally accepted clinical guidelines through expert consensus, enhancing trial reporting standards to improve research quality, and fostering interdisciplinary, cross-regional collaboration to drive innovation and systemic impact.
''Evolving Legacy' demonstrates how Chinese Medicine research has matured into a global, evidence-informed field,' said Professor Lyu Aiping, Vice-President (Research & Development), HKBU, and a leading expert in Chinese Medicine. 'We envision a future where data science and AI illuminate what Chinese Medicine research has long intimated, providing deeper insights into health classifications and compound interventions. The next frontier is using Chinese Medicine research to uncover insights possibly overlooked in Digital Health and Systems Medicine, strengthening their scientific foundation and impact.'
'This report offers unprecedented insights into Chinese Medicine's evolving scientific landscape,' added Basak Candemir, Business Development Director, Analytical and Data Services, Elsevier. 'It illuminates the growing global impact of Chinese Medicine research and its role in diversified healthcare solutions, making a vital step towards bridging traditional knowledge with modern validation for the benefit of global health.'
The report was developed using Elsevier's bibliometric tools, Scopus and SciVal, based on a comprehensive dataset and case studies compiled in collaboration with HKBU Chinese Medicine research experts. The report can be accessed on https://cm-evaluation.scm.hkbu.edu.hk/.
Hashtag: #HKBU
The issuer is solely responsible for the content of this announcement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
a day ago
- Zawya
HKBU-led research develops novel drug delivery system for Gouteng compound for Alzheimer's disease treatment
Asia Press Release HONG KONG SAR - Media OutReach Newswire - 6 December 2023 - A research team led by Hong Kong Baptist University (HKBU) has developed a novel drug delivery system for Alzheimer's disease (AD). The researchers have engineered exosomes, extracellular vesicles released by cells, to effectively carry the bioactive compound Corynoxine-B extracted from the Chinese herbal medicine Gouteng to the brain of mice with AD. As Corynoxine-B can induce autophagy, a process that maintains the health of cells, this new drug delivery system using exosomes can improve cognitive function and movement while reducing the symptoms of AD. The research findings have been published in the international academic journal Nature-Signal Transduction and Targeted Therapy. Bioactive compound of Gouteng can treat AD AD is the most common type of dementia in which the brain cells degenerate and die, characterised by a build-up of amyloid-beta and phospho-tau protein in the brain, resulting in the decline of the brain's cognitive functions. Currently more than 55 million people worldwide are dementia patients. In Hong Kong more than 100,000 elderly suffer from dementia and the number is anticipated to soar to more than 330,000 by 2039. At present there is no curative treatment for AD. Available treatments can only delay the disease's progression and improve symptoms. HKBU's previous research projects found that Corynoxine-B, a bioactive compound of Gouteng, is effective in treating AD. However, the blood-brain barrier which protects the brain from potentially harmful substances in the bloodstream affects its uptake in brain. Exosomes serve as drug carriers To tackle this problem, a research team comprising Professor Li Min, Associate Dean (Teaching and Learning) of Chinese Medicine, and Dr Ashok Iyaswamy, Research Assistant Professor of the Teaching and Research Division at the School of Chinese Medicine at HKBU, along with other local, mainland and overseas scientists, have developed a novel approach to deliver Corynoxine-B to the brain using exosomes. Exosomes are extracellular vesicles released by cells which can transport molecules between cells like nanocarriers. Recent studies have shown that they could be utilised as vehicles for drug delivery. To examine whether exosomes are effective drug carriers for AD, the researchers manipulated the neuronal cells in mice to overexpress an adaptor protein Fe65 on the surface of exosomes released by these cells. Fe65 is involved in the processing of amyloid-beta precursor protein (APP), which plays a crucial role in the development of AD. By doing so, they observed more exosomes containing Fe65 were released by the neuronal cells. These engineered exosomes showed a good ability to migrate towards the neuronal cells with APP overexpressed in AD models. These findings suggest that the presence of Fe65 on the surface of exosomes enhanced their ability to specifically target and interact with the neuronal cells with elevated levels of APP, which is a characteristic feature of AD. Reduction of accumulated amyloid-beta protein Corynoxine-B is a natural inducer of autophagy which plays a crucial role in maintaining neuronal health. The research team loaded it into the engineered exosomes and injected it to the mice with AD to evaluate its potential as a therapeutic agent for the disease. Results show that engineered exosomes loaded with Corynoxine-B could enhance autophagy in mice, and were able to cross the blood-brain barrier to deliver Corynoxine-B to the brain, resulting in a 30% reduction of accumulated amyloid-beta protein. In addition, various behavioural tests including the rotarod test, open field test, contextual fear conditioning test, and Morris's water maze test conducted on mice with AD showed that the application of engineered exosomes loaded with Corynoxine-B resulted in 25% recovery of the cognitive and locomotor behaviour. Professor Li Min said: "Our study suggests that exosomes could be a promising new way to deliver drugs to the brain and treat AD. More research is needed, but this study provides hope that a cure for AD may be possible in the future. We hope that this research project will ultimately be beneficial to the elderly, individuals at high risk of neurodegeneration and neurodegenerative disease patients." Hashtag: #Alzheimer'sdisease The issuer is solely responsible for the content of this announcement. Hong Kong Baptist University Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an 'as is' and 'as available' basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release. The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk. To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
Web Release
a day ago
- Web Release
Bellevue Medical Center Celebrates 15 Years of Leadership
As part of its unwavering commitment to providing advanced, innovation-driven, patient-centered healthcare, and its continued efforts to elevate the standing of Lebanon and its healthcare sector on both the regional and global levels, Bellevue Medical Center (BMC) proudly marked its 15th anniversary with a special dinner, bringing together staff, nursing professionals, physician representatives, media, and the administrative team. The celebratory event underscored the hospital's core belief: success is a collective achievement, forged by the dedication and hard work of every individual. For a decade and a half, Bellevue Medical Center has consistently upheld its renowned high standards of care, navigating Lebanon's profound challenges, including the COVID-19 pandemic, economic crises, and the devastating Beirut Port explosion. Throughout these difficult times, Bellevue Medical Center, has remained steadfast in its commitment to delivering top-tier healthcare, continuously growing and enhancing its services through cutting-edge technologies and investments in artificial intelligence to drive superior patient outcomes. This unwavering dedication demonstrates that even amidst adversity, a strong focus on quality care and human compassion truly makes a difference. Bellevue's journey is marked by groundbreaking achievements, including performing the Middle East and North Africa's first uterus transplants under clinical research in 2018, which notably resulted in successful live births. The hospital's unwavering commitment to global healthcare quality and safety is further evidenced by its multiple accreditations from Joint Commission International (JCI). BMC also received the Excellence in Sustainability Award and earned five certifications from the Arab Hospitals Federation for its environmental leadership, part of the Arab Health Climate Challenge Gold Seal Initiative. Beyond medical innovation, Bellevue Medical Center is deeply committed to the human element of healthcare. Repeatedly certified by Planetree International, BMC champions a patient-centered approach that embraces the body, mind, and spirit. Further testament to this philosophy, Bellevue's CEO, Mr. Nayef Maalouf, was honored with Planetree International's prestigious 'Caregiver of the Year' award in 2023 for his dedication to person-centered care. During the anniversary celebration, Mr. Nayef Maalouf expressed his gratitude to all who have contributed to the hospital's journey. 'Everything we have achieved over the past fifteen years has been possible because of our teamwork, our passion for care, our strong belief in our mission, and the trust of our patients and community even during the toughest times,' Mr. Maalouf stated. 'This celebration isn't just about looking back; it's about moving forward and building the future. We are focused on growing, advancing healthcare medicine for better patients outcomes, and ensuring Lebanon and its healthcare professionals are recognized at both national and international levels.' As it celebrates this milestone, Bellevue Medical Center reaffirms its commitment to innovation, sustainability, and putting patients at the heart of everything it does. With vision and determination, Bellevue continues to be a trusted provider of advanced, compassionate care for Lebanon and the region.
Arabian Post
2 days ago
- Arabian Post
Hong Kong Baptist University and Elsevier Report Highlights Global Expansion of Chinese Medicine Research, Urges Standardised Frameworks for Broader Integration
HKBU and Elsevier launched a new report 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine', highlighting the growing global impact of Chinese Medicine research in diversified healthcare solutions. ISTANBUL, TURKEY – Media OutReach Newswire – 18 June 2025 – The report 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine' released today by Hong Kong Baptist University (HKBU) and Elsevier, reveals the growing impact of Chinese Medicine research on global healthcare and modern health challenges. In this context, 'Chinese Medicine research' encompasses not only clinical practice, but also basic and translational science, AI-driven systems medicine, and the network pharmacology of herbal formulas. This first bibliometric analysis of Chinese Medicine research from 2014 to 2023 highlights the field's rapid growth, interdisciplinarity, and societal impact on Digital Health and Systems Medicine. Key findings from the report include: Rapid expansion : Chinese Medicine research grew at a 10.6% compound annual growth rate — more than double the global research average — nearly tripling output between 2014 and 2023. : Chinese Medicine research grew at a 10.6% compound annual growth rate — more than double the global research average — nearly tripling output between 2014 and 2023. High scholarly impact : 14.2% of Chinese Medicine papers ranked among the world's top 10% most-cited (global norm: 10%), with a field-weighted citation impact (FWCI) of 1.12. : 14.2% of Chinese Medicine papers ranked among the world's top 10% most-cited (global norm: 10%), with a field-weighted citation impact (FWCI) of 1.12. Interdisciplinary breadth : Medicine dominates (61.9% of output), followed by Biochemistry, Genetics & Molecular Biology (33.1%) and Pharmacology (28.1%). Citing publications span diverse major domains — from Engineering to Materials Science. : Medicine dominates (61.9% of output), followed by Biochemistry, Genetics & Molecular Biology (33.1%) and Pharmacology (28.1%). Citing publications span diverse major domains — from Engineering to Materials Science. Global collaboration hubs : Hong Kong SAR and Macao SAR exceed 80% cross-regional collaboration, above the 18% world average, and achieving FWCI >1.6 in cross-regional collaborative publications. : Hong Kong SAR and Macao SAR exceed 80% cross-regional collaboration, above the 18% world average, and achieving FWCI >1.6 in cross-regional collaborative publications. Emerging research foci : Top-published trending topics include 'Herbaceous Agent | Chinese Medicine | Network Pharmacology' and COVID-19 applications, reflecting integration of omics, AI and systems methods. : Top-published trending topics include 'Herbaceous Agent | Chinese Medicine | Network Pharmacology' and COVID-19 applications, reflecting integration of omics, AI and systems methods. Societal resonance: 11.1% of research outputs were mentioned on social media and 2.9% cited in policy documents, reflecting growing public and policymaker interest. Bridging a global integration gap ADVERTISEMENT Chinese Medicine's mainstream integration lacks a global, transparent, evidence-based framework. To elevate its scientific profile, key strategies include developing internationally accepted clinical guidelines through expert consensus, enhancing trial reporting standards to improve research quality, and fostering interdisciplinary, cross-regional collaboration to drive innovation and systemic impact. ''Evolving Legacy' demonstrates how Chinese Medicine research has matured into a global, evidence-informed field,' said Professor Lyu Aiping, Vice-President (Research & Development), HKBU, and a leading expert in Chinese Medicine. 'We envision a future where data science and AI illuminate what Chinese Medicine research has long intimated, providing deeper insights into health classifications and compound interventions. The next frontier is using Chinese Medicine research to uncover insights possibly overlooked in Digital Health and Systems Medicine, strengthening their scientific foundation and impact.' 'This report offers unprecedented insights into Chinese Medicine's evolving scientific landscape,' added Basak Candemir, Business Development Director, Analytical and Data Services, Elsevier. 'It illuminates the growing global impact of Chinese Medicine research and its role in diversified healthcare solutions, making a vital step towards bridging traditional knowledge with modern validation for the benefit of global health.' The report was developed using Elsevier's bibliometric tools, Scopus and SciVal, based on a comprehensive dataset and case studies compiled in collaboration with HKBU Chinese Medicine research experts. The report can be accessed on Hashtag: #HKBU The issuer is solely responsible for the content of this announcement.
